Cost determinants among adults hospitalized with respiratory syncytial virus in the United States, 2017-2019.
Yoonyoung ChoiAlexandra Hill-RicciutiAngela R BrancheWilliam D SielingLisa SaimanEdward E WalshMatthew PhillipsAnn R FalseyLyn FinelliPublished in: Influenza and other respiratory viruses (2021)
The economic burden of RSV hospitalization of adults ≥ 18 years of age in the United States is substantial. RSV vaccine programs may be useful in reducing this economic burden.
Keyphrases